Enjoy complimentary customisation on priority with our Enterprise License!
The recombinant proteins market size is estimated to grow at a CAGR of 9.46% between 2022 and 2027. The market size is forecast to increase by USD 650.96 million. The growth of the market depends on several factors, including an increase in chronic diseases, a rising inclination toward biologics and biosimilars, and technological advancements in the production of recombinant proteins.
This recombinant proteins market report extensively covers market segmentation by application (biotechnology research, drug discovery and development, biopharmaceutical production, and others), end-user (pharma and biotechnology companies, academic and research institutes, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The increase in chronic diseases is notably driving the market growth, although a complicated regulatory framework may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
An increase in chronic diseases is notably driving the recombinant proteins market growth. Major chronic diseases such as cancer, cardiovascular, endocrine, and viral diseases are all being treated with recombinant proteins. During the forecast period, the increasing prevalence of such types of diseases is expected to boost the demand for recombinant proteins. The World Health Organization estimates that cancer is the second leading cause of death worldwide. About 1 in 6 deaths worldwide is caused by cancer.
Cardiovascular disease is caused by high blood pressure, high cholesterol, obesity, unhealthy diet, lack of exercise, and smoking. The prevalence of cardiovascular disease and cancer is increasing worldwide. Similarly, the increasing prevalence of other chronic diseases, such as cardiovascular diseases and neurological disorders, will increase the demand for recombinant proteins during the forecast period.
Growing opportunities from emerging economies is a key trend influencing the recombinant proteins market growth. With diverse healthcare markets, the rising prevalence of infectious and chronic diseases, and increasing R&D efforts to develop cutting-edge proteomics and genomics methods, emerging markets such as Asia offer great potential for market participants. In addition to these factors, market participants are encouraged to invest in the region of an aging population, rising income levels, improved healthcare infrastructure, rising healthcare costs, and the region's leadership in low-cost manufacturing. Asia's regulatory framework is also more flexible and business-friendly, attracting larger companies that are already struggling with stiff competition in established markets.
Additionally, governments in several emerging countries in Asia are taking steps to raise awareness of cancer and its diagnosis so that it can be detected early. For example, the health minister of the Indian state of Tamil Nadu said that the government of Tamil Nadu will help identify 66% of stage 1 and stage 2 cancer patients by 2030. He said he was working on developing policies for proper treatment. Consequently, such policies are expected to boost the growth of the market during the forecast period.
A complicated regulatory framework is challenging the recombinant proteins market growth. Obtaining regulatory approval is often difficult, unpredictable, and subjective. Recombinant proteins are subject to extensive and stringent regulations before approval and commercialization. From a global perspective, the United States currently lags behind other regulated markets, particularly the European Union (EU), in the biosimilar race. The US biosimilar industry continues to attract attention despite the lack of new entrants. The first and most important factor expected to determine the future of biosimilars in the United States has to do with the approval of the regulatory framework within which biosimilar developers must operate.
In Europe, strict regulations are applied to ensure their safety and effectiveness in protecting people. However, most European countries have good market traction as the approval process is a bit faster than in the US. The inability of a provider to provide clinical data showing positive results in a particular region can incur costs, create uncertainty, and confound other studies. This may create barriers for vendors to develop new protein therapeutics in the market and may adversely affect the growth of the market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Recombinant Proteins Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abcam plc: The company is involved in the production, distribution, and sales of antibodies and protein research tools. It also offers different types of recombinant proteins, such as bioactive grade proteins and others.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the biotechnology research segment will be significant during the forecast period. The broad field of biotechnology involves the use of biological processes, animals, cells, or cell components to develop new technologies. Recombinant proteins have contributed to significant advances in biomedical biotechnology. More and more recombinant proteins are being used in laboratories. This includes proteins generated in course-specific research projects as well as commercially available proteins (such as most enzymes used in molecular biology laboratories). Recombinant lysosomal proteins are often made by mammalian cells. FDA-approved glycosylated lysosomal protein drugs and other drug candidates were developed using plant cell culture. Recombinant lysosomal proteins can be produced using microorganisms such as Saccharomyces cerevisiae and Escherichia coli. There are both scientific and medical uses for recombinant lysosomal proteins, including enzyme replacement therapy. Such factors drive the growth of the market during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The biotechnology research segment was valued at USD 416.71 million in 2017 and continued to grow until 2021. Recombinant proteins are a useful resource for understanding how proteins interact with each other. They have demonstrated their efficacy in various laboratory tests such as ELISA, Western blot, and immunohistochemistry (IHC). Enzymatic assays can be created using recombinant proteins. Recombinant proteins are also used in food production, agriculture, and biotechnology. In addition, researchers have used genetic techniques to modify proteins to create recombinant therapeutic proteins. In general, the development of biotechnology has facilitated the production of recombinant proteins for various applications. Such factors drive the growth of the market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 35% to the growth of the global recombinant proteins market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in the North American region is growing rapidly due to the higher uptake of recombinant proteins. The major driving force for the market in this region is the increasing prevalence of cancer, autoimmune diseases, metabolic diseases, musculoskeletal diseases, central nervous system diseases, hematological diseases, etc. The prevalence of cardiovascular disease and cancer is increasing worldwide. Therefore, the demographic and economic growth in this region is expected to present great opportunities for the market. Factors such as rising R&D spending, increasing research activity, favorable government funding, and the presence of key players in the region are boosting the market expansion during the forecast period.
COVID-19 in 2020 severely impacted the market. The exponential increase in the number of COVID-19 cases forced governments of various countries across the world to impose restrictions on business and transportation activities, leading to the closure of laboratories and clinical research centers. The pandemic reduced recombinant protein production due to government restrictions on people's movement. In 2021, the start of vaccination program resumed business operations, including the recombinant protein supply chain. The market witnessed positive growth in 2021, owing to rising demand for recombinant protein to contain the threat of COVID-19.
The recombinant proteins market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global recombinant proteins market as a part of the global biotechnology market within the overall healthcare industry. The parent, the global biotechnology market, is involved in the research and development (R&D) or production of all types of biotechnology products, such as biologics, biosimilars, biobetters, and biotechnology reagents. Technavio calculates the global healthcare market size based on the total revenue generated by manufacturers/suppliers of equipment, consumables, pharmaceuticals, biotechnology, life science tools, and services.
|
Recombinant Proteins Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
167 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.46% |
|
Market growth 2023-2027 |
USD 650.96 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
9.0 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 35% |
|
Key countries |
US, Germany, Italy, China, and Japan |
|
Competitive landscape |
Leading vendors, market positioning of vendors, competitive strategies, and industry risks |
|
Key companies profiled |
Abcam plc, Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Bio Techne Corp., Bio Rad Laboratories Inc., BPS Bioscience Inc., Elabscience Biotechnology Inc., Enzo Biochem Inc., GenScript Biotech Corp., Grifols SA, Merck KGaA, Novartis AG, Novo Nordisk AS, OriGene Technologies Inc., Prospec Tany Technogene Ltd., Proteintech Group Inc., Sanofi SA, Sino Biological Inc., and Thermo Fisher Scientific Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
